^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Head and Neck Cancer
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

    Excerpt:
    ...- Participant must have a documented RET-fusion...
    Trial ID:
    AcceleRET Lung
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    Excerpt:
    ...- participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion previously treated with a platinum-based chemotherapy....
    Trial ID:
    ARROW
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

    Excerpt:
    ...- Must have a diagnosis of locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC...
    Trial ID:
    NCT04697446
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Nat Med
    Title:

    Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Published date:
    08/12/2022
    Excerpt:
    ...here we present interim data on the efficacy and safety of pralsetinib in prospectively identified patients with diverse RET fusion–positive tumors....Confirmed tumor responses were observed in all four patients with pancreatic cancer (including one CR), two of three patients with cholangiocarcinoma, two of three patients with sarcoma (including one CR), two of three patients with neuroendocrine cancer and single patients with head and neck cancer and unknown primary tumor (CR).
    DOI:
    https://doi.org/10.1038/s41591-022-01931-y
    Trial ID:
    ARROW